Oncology

NFlection Therapeutics’ NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial

06/02/2021

Excerpt from the Press Release: WAYNE, Pa., May 26, 2021 /PRNewswire/ — NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for rare disorders driven by aberrant activation of the RAS pathway (RASopathies), today announced positive results from a 28-day, Phase 2a, multicenter, randomized, double-blind, parallel-group, vehicle-controlled clinical trial investigating the safety, tolerability,…

Read More

The Lancet Publishes Results of Axumin® (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer

06/01/2021

Excerpt from the Press Release: BURLINGTON, Mass. & OXFORD, England–(BUSINESS WIRE)–Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin® (fluciclovine F 18) PET…

Read More

Phase 3 OCEAN study demonstrates that melphalan flufenamide is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma

05/31/2021

Excerpt from the Press Release: Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces positive topline results from the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melphalan flufenamide versus pomalidomide in patients with relapsed refractory multiple myeloma (RRMM).…

Read More

AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells

05/30/2021

Excerpt from the Press Release: SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) — AXIM®Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has completed pre-clinical drug studies on its patent pending compound SPX-1009, demonstrating the suppression of malignant metastatic melanoma cells. The…

Read More

Freenome Presents Data Demonstrating the Importance of Clinical Test Performance and Screening Adherence on Colorectal Cancer Outcomes

05/27/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Freenome, the privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results from two different studies using “CRC – Microsimulation of Adenoma Progression and Screening”, or CRC-MAPS™, a novel semi-Markov microsimulation model of…

Read More

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

05/25/2021

Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the combination of its investigational RAF/MEK inhibitor VS-6766, with defactinib, its FAK inhibitor, for…

Read More

Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of ON 123300

05/24/2021

Excerpt from the Press Release: NEWTOWN, Pa., May 21, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company’s proprietary, novel…

Read More

Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia

05/18/2021

Excerpt from the Press Release: SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced encouraging interim Phase 1 data from the Company’s off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML). The ongoing…

Read More

Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma

05/17/2021

Excerpt from the Press Release: SAN CARLOS, Calif., May 12, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced that the Journal of Clinical Oncology has published a manuscript of clinical data for Cohort 2 in the C-144-01…

Read More

Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients

05/14/2021

Excerpt from the Press Release: WALNUT CREEK, CA and LONDON, UK / ACCESSWIRE / May 3, 2021 / Vivacitas Oncology, Inc. (“Vivacitas” or the “Company“), a clinical stage biopharmaceutical company focused on tough to treat cancers, and Image Analysis Group (“IAG”), a leading global medical imaging company, are collaborating to apply Artificial Intelligence (AI) technology and…

Read More